Use of GLP-1 receptor agonists in patients with T2DM and chronic kidney disease

被引：1
|
作者：
Aldrich, Sarah [1 ]
Ashjian, Emily [2 ]
机构：
[1] Univ Toledo, Coll Pharm & Pharmaceut Sci, 2801 W Bancroft St, Toledo, OH 43606 USA
[2] Univ Michigan, Coll Pharm, 428 Church St, Ann Arbor, MI 48109 USA
来源：
NURSE PRACTITIONER | 2019年 / 44卷 / 03期
关键词：
chronic kidney disease; diabetes; dialysis; dulaglutide; end-stage renal disease; exenatide; glucagon-like peptide-1 receptor agonist; liraglutide; lixisenatide; semaglutide; type 2 diabetes mellitus; CARDIOVASCULAR OUTCOMES; TYPE-2; RISK; EXENATIDE; SAFETY; PHARMACOKINETICS; LIXISENATIDE; TOLERABILITY; DULAGLUTIDE; MORTALITY;
D O I：
10.1097/01.NPR.0000553396.65976.bb
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
Diabetes mellitus is the leading cause of chronic kidney disease (CKD) in the US. An increasing number of glucagon-like peptide-1 receptor agonists are available for diabetes management. Differences between medications in this class, as well as limited data on patients with CKD, underscore the importance of a patient-centered approach to care.
引用
收藏
页码：20 / 28
页数：9
相关论文
共 50 条
  • [41] GLP-1 receptor agonists in NAFLD
    Petit, J. -M.
    Verges, B.
    DIABETES & METABOLISM, 2017, 43 : 2S28 - 2S33
  • [42] GLP-1 receptor agonists for type 2 diabetes
    De Block, Christophe E. M.
    Van Gaal, Luc F.
    LANCET, 2009, 374 (9683): : 4 - 6
  • [43] Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis
    Kelly, Michael
    Lewis, Jelena
    Rao, Hindu
    Carter, Jessica
    Portillo, Ivan
    Beuttler, Richard
    PHARMACOTHERAPY, 2022, 42 (12): : 921 - 928
  • [44] Emerging GLP-1 receptor agonists
    Lund, Asger
    Knop, Filip K.
    Vilsboll, Tina
    EXPERT OPINION ON EMERGING DRUGS, 2011, 16 (04) : 607 - 618
  • [45] GLP-1 receptor agonists today
    Marre, Michel
    Penfornis, Alfred
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 93 (03) : 317 - 327
  • [46] The Future of the GLP-1 Receptor Agonists
    Hirsch, Irl B.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (15): : 1457 - 1458
  • [47] Positioning on GLP-1 receptor agonists
    Gimenez, Sergio
    Piskorz, Daniel
    Martinez Demaria, Diego
    Nanfara, Silvia
    Lorenzatti, Alberto
    Zapata, Gerardo
    Aguinaga Arrascue, Luis
    Perna, Eduardo
    REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2021, 50 : 4 - 10
  • [48] A New Hope on the Horizon for Kidney and Cardiovascular Protection with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Mineralocorticoid Receptor Antagonists in Type 2 Diabetic and Chronic Kidney Disease Patients
    Spasovski, Goce
    Rroji, Merita
    Hristov, Goce
    Bushljetikj, Oliver
    Spahia, Nereida
    Bushletikj, Irena Rambabova
    METABOLIC SYNDROME AND RELATED DISORDERS, 2024, 22 (03) : 170 - 178
  • [49] Risk of thyroid cancer with the use of GLP-1 receptor agonists
    Gouverneur, Amandine
    Penichon, Marine
    Garrel, Renaud
    Hillaire-Buys, Dominique
    Pariente, Antoine
    Faillie, Jean-Luc
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 330 - 330
  • [50] GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art
    Granata, Antonio
    Maccarrone, Rosario
    Anzaldi, Massimiliano
    Leonardi, Giuseppe
    Pesce, Francesco
    Amico, Francesco
    Gesualdo, Loreto
    Corrao, Salvatore
    CLINICAL KIDNEY JOURNAL, 2022, 15 (09) : 1657 - 1665
12345